ORLANDO, Fla. — The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.
"We are grateful for the vision and support of the 2012 board of directors, and we are excited to move ahead with our chairman and our 2013 board," GPhA president and CEO Ralph Neas said. "In a time of enormous change and growth for our industry, leadership is critical."
Mylan North America president Tony Mauro was elected as chairman for a second year, having served as chairman in 2012. The GPhA's rules stipulate that a chairman or chairwoman can be elected for up to two one-year terms.
"I'm honored to have been elected to serve a second term as chairman of GPhA's board of directors," Mauro said. "The role that the generics industry plans in providing sustainable healthcare solutions for patients in the United States and around the world has never been more important."
The board for this year includes Don DeGolyer, president and CEO of Sandoz US, elected as vice chairman; Craig Wheeler, president and CEO of Momenta Pharmaceuticals, elected as secretary treasurer; Debra Barrett, SVP global government affairs and public policy of Teva Pharmaceuticals; Carole Ben-Maimon, president for global pharmaceuticals of Impax Labs; Doug Boothe, EVP and general manager of Perrigo Pharmaceuticals; Chuck Caprariello, VP corporate communications and government affairs of Ranbaxy; John Ducker, president and CEO of Fresnius-Kabi USA; Jeffrey Glazer, president and CEO of Heritage Pharmaceuticals; Charlie Mayr, global chief communications officer of Actavis; Thomas Moore, U.S. president of Hospira; Chirag Patel, CEO of Amneal Pharmaceuticals; Joseph Renner, president and CEO of Zydus Pharmaceuticals USA; George Stevenson, president and CEO of Kremers-Urban Pharmaceuticals; and Jeff Watson, president of Apotex.